SRDX (Surmodics Corp) Company Projected Revenue

Geopolitical instability and logistics disruptions are hindering equipment sales for Surmodics, Inc. (SRDX), which clearly demonstrates the company's planned sales levels. The latest parameter stands at 0.12. Strict FDA certification and coating patents provide fundamental stability, while high-demand solutions for minimally invasive surgeries support growth potential.

SRDX - Surmodics Inc. Company Expected Sales Volume over the range 07/04/2022 - 11/29/2025

Analytical breakdowns and data insights for company Surmodics Inc (SRDX)

- current price and projected stock value:

Stock Quotes Surmodics, Inc.|SRDX - Fair Value Consensus

- business market valuation indicators:

Market Value Surmodics Inc|SRDX - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share Surmodics|SRDX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio surmodics.com|SRDX - Total Business Assets

- issuer credit burden and liquidity indicators:

- earnings and market ratios statistics:

SRDX - Final Profit|Projected Future Earnings Surmodics, Inc.|SRDX - Market Cap to Earnings|Future Price to Earnings Surmodics|SRDX - Price to Net Income Growth Ratio|Enterprise Value to EBITDA Ratio Surmodics Inc|SRDX - Operating profit EBITDA|Net earnings per share (EPS TTM) Surmodics|SRDX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months surmodics.com|SRDX - Earnings per share trend in current year|Net earnings per share growth forecast for next year Surmodics, Inc.

- sales and revenue data:

SRDX - Company Sales|Projected Sales Volume Surmodics, Inc.|SRDX - Price to Sales|Price-to-Projected Revenue Ratio Surmodics Inc

Fundamental company analysis:Surmodics, Inc.

This indicator forecasts future revenue, allowing for the identification of hidden business degradation behind the apparent cheapness of an asset by analyzing the balance of supply and demand. Using this benchmark for the firm's sales volume, an investor assesses the stability of Surmodics, Inc. (SRDX), where steady royalties from biomaterials minimize costs and ensure a confident cash flow surplus with low expenditures.

Analysis of competing companies